NRAS and acute myeloid leukemia: Patients with DNMT3A (P<0.001), STAG2 (P<0.001), NPM1 (P=0.042) and NRAS (P<0.001) mutations showed significantly poorer AML-free survival (AFS) in univariate analysis (Supplementary Table S4).